VIVO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-05), Meridian Bioscience's current share price is $33.97. Meridian Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $6.26. Meridian Bioscience's Cyclically Adjusted PS Ratio for today is 5.43.
The historical rank and industry rank for Meridian Bioscience's Cyclically Adjusted PS Ratio or its related term are showing as below:
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Meridian Bioscience's adjusted revenue per share data for the three months ended in Sep. 2022 was $1.466. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.26 for the trailing ten years ended in Sep. 2022.
The historical data trend for Meridian Bioscience's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meridian Bioscience Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 3.46 | 3.56 | 4.31 | 4.88 | 5.04 |
For the Diagnostics & Research subindustry, Meridian Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Meridian Bioscience's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Meridian Bioscience's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 33.97 | / | 6.26 | |
= | 5.43 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meridian Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 is calculated as:
For example, Meridian Bioscience's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2022 (Change) | * | Current CPI (Sep. 2022) |
= | 1.466 | / | 125.2265 | * | 125.2265 | |
= | 1.466 |
Current CPI (Sep. 2022) = 125.2265.
Meridian Bioscience Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201212 | 1.086 | 96.871 | 1.404 |
201303 | 1.127 | 98.209 | 1.437 |
201306 | 1.122 | 98.518 | 1.426 |
201309 | 1.166 | 98.790 | 1.478 |
201312 | 1.064 | 98.326 | 1.355 |
201403 | 1.190 | 99.695 | 1.495 |
201406 | 1.122 | 100.560 | 1.397 |
201409 | 1.126 | 100.428 | 1.404 |
201412 | 1.145 | 99.070 | 1.447 |
201503 | 1.226 | 99.621 | 1.541 |
201506 | 1.145 | 100.684 | 1.424 |
201509 | 1.119 | 100.392 | 1.396 |
201512 | 1.114 | 99.792 | 1.398 |
201603 | 1.208 | 100.470 | 1.506 |
201606 | 1.193 | 101.688 | 1.469 |
201609 | 1.108 | 101.861 | 1.362 |
201612 | 1.100 | 101.863 | 1.352 |
201703 | 1.271 | 102.862 | 1.547 |
201706 | 1.177 | 103.349 | 1.426 |
201709 | 1.166 | 104.136 | 1.402 |
201712 | 1.226 | 104.011 | 1.476 |
201803 | 1.321 | 105.290 | 1.571 |
201806 | 1.210 | 106.317 | 1.425 |
201809 | 1.238 | 106.507 | 1.456 |
201812 | 1.200 | 105.998 | 1.418 |
201903 | 1.170 | 107.251 | 1.366 |
201906 | 1.129 | 108.070 | 1.308 |
201909 | 1.186 | 108.329 | 1.371 |
201912 | 1.104 | 108.420 | 1.275 |
202003 | 1.333 | 108.902 | 1.533 |
202006 | 1.960 | 108.767 | 2.257 |
202009 | 1.472 | 109.815 | 1.679 |
202012 | 2.122 | 109.897 | 2.418 |
202103 | 1.932 | 111.754 | 2.165 |
202106 | 1.440 | 114.631 | 1.573 |
202109 | 1.731 | 115.734 | 1.873 |
202112 | 2.006 | 117.630 | 2.136 |
202203 | 2.513 | 121.301 | 2.594 |
202206 | 1.524 | 125.017 | 1.527 |
202209 | 1.466 | 125.227 | 1.466 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Meridian Bioscience's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Julie Diana Smith | officer: Sr VP, Controller, PAO | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
John P. Kenny | director, officer: Chief Executive Officer | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Andrew S. Kitzmiller | officer: EVP & CFO | ONE BATESVILLE BLVD., BATESVILLE IN 47006 |
Bryan T Baldasare | officer: Interim CFO & Chief Acctg Off | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Rice John Mccune Jr. | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Bihl Anthony P Iii | director | 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840 |
Tony Serafini-lamanna | officer: Executive VP-Diagnostics | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Felicia Williams | director | C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001 |
John Mcilwraith | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
David Phillips | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
James M. Anderson | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Dwight E Ellingwood | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Lawrence Baldini | officer: Exec VP, Operations & IS | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric S. Rasmussen | officer: EVP, Bus. Development/Strategy | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Lourdes Weltzien | officer: EVP, Life Science | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
From GuruFocus
By PRNewswire PRNewswire • 07-28-2022
By PurpleRose PurpleRose • 07-11-2022
By GuruFocus Research GuruFocus Editor • 11-03-2022
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 06-12-2022
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 07-12-2022
By PRNewswire PRNewswire • 01-31-2023